Dr. Paika Podcast

#PCOS #GLP1 #PMOS #Semaglutide #Tirzepatide

Not losing weight on GLP-1 with PCOS? You're not imagining it, and it's not a willpower problem. In this video, I explain why semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) can stall in women with PCOS, now officially renamed PMOS (polyendocrine metabolic ovarian syndrome), and the 4 things doctors do to get weight loss moving again.

You'll learn the 3 hormonal roadblocks behind a PCOS stall (high insulin, androgens and belly fat, and your own GLP-1 system), why standard dosing often isn't enough, how tirzepatide compares with semaglutide, when metformin or inositol makes sense, which labs to track (fasting insulin, HOMA-IR, free testosterone, SHBG, TSH, A1c and lipids), and how to tell your treatment is working even when the scale isn't.

๐ŸŽ“ Complete GLP-1 Weight Loss Masterclass โ€” Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

๐Ÿ“ฉ FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

Timestamps

00:00 Why GLP-1 weight loss stalls with PCOS
00:55 About me
01:21 PCOS is now PMOS: why the name changed
02:36 Insulin resistance in PCOS: the numbers
03:12 Roadblock #1: Hyperinsulinemia
04:44 Roadblock #2: Androgens and belly fat
06:10 Muscle: a shortcut around insulin resistance
06:57 Roadblock #3: Your own GLP-1 system
07:55 Why standard GLP-1 dosing stalls
09:11 Metabolic adaptation and normal plateaus
09:51 Fix #1: Right drug, right dose
10:36 Tirzepatide vs semaglutide (and PCOS data)
11:39 Retatrutide
11:56 Pregnancy and birth control on GLP-1s
12:22 Fix #2: Metformin, combination therapy and inositol
13:57 Fix #3: Labs to track, not just the scale
15:33 Fix #4: Body composition and protecting muscle
16:39 Non-scale wins to watch
17:09 GLP-1 Masterclass
17:30 Summary and what happens if you stop

References

1. Teede HJ, et al. 2023 International Evidence-based Guideline for PCOS. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
2. PCOS renamed PMOS. The Lancet, May 12, 2026; Monash/MCHRI terminology summary, 2026.
3. Stepto NK, et al. Hum Reprod. 2013;28(3):777-784.
4. Cassar S, et al. Hum Reprod. 2016;31(11):2619-2631.
5. Nestler JE. Semin Reprod Endocrinol. 1997;15(2):111-122.
6. O'Reilly MW, et al. J Clin Endocrinol Metab. 2017;102(9):3327-3339.
7. Zhu S, et al. Front Endocrinol. 2021;12:697223.
8. Karolinska Institutet doctoral thesis on adipocyte lipolysis in PCOS.
9. Moro C, et al. J Clin Endocrinol Metab. 2009;94(7):2579-2586.
10. Aydin K, et al. Clin Endocrinol. 2014;81(4):588-592.
11. GรผneลŸli I, et al. Endocrine Abstracts. 2025;110:RC5.2.
12. An impaired GLP-1 response is associated with prediabetes in PCOS with obesity. PMC6833370.
13. Glintborg D, et al. Endocr Connect. 2017;6(4):267-277.
14. Wegovy (semaglutide) US Prescribing Information, including Wegovy HD 7.2 mg (FDA, 2026).
15. Zepbound (tirzepatide) US Prescribing Information.
16. Carmina E, Longo RA. J Clin Med. 2023;12(18):5921.
17. Alawami F, et al. Ir J Med Sci. 2026;195(1):131-136.
18. Fothergill E, et al. Obesity. 2016;24(8):1612-1619.
19. Thomas MK, et al. J Clin Endocrinol Metab. 2021;106(2):388-396.
20. Tirzepatide vs semaglutide on beta-cell function and insulin sensitivity. J Clin Endocrinol Metab. 2024;109(12):3046-3054.
21. Aronne LJ, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.
22. Clift AK, et al. J Endocr Soc. 2026;10(9):bvag177.
23. PERIODS trial (tirzepatide in PCOS). ClinicalTrials.gov NCT07326111.
24. Jastreboff AM, et al. TRIUMPH-1 (retatrutide). N Engl J Med. 2026.
25. Jensterle M, et al. Exp Ther Med. 2016;11(4):1194-1200.
26. Zhang W, et al. Metab Target Organ Damage. 2026;6:10.
27. Fitz V, et al. J Clin Endocrinol Metab. 2024;109(6):1630-1655.
28. Matthews DR, et al. Diabetologia. 1985;28(7):412-419.
29. Ding X, et al. Front Endocrinol. 2018;9:700.
30. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002; Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216.
31. Jensterle M, et al. Front Endocrinol. 2024;15:1366940.

โš•๏ธ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

What is Dr. Paika Podcast?

Welcome to the Dr. Paika Podcast โ€” where medicine, fitness, and humanity come together.

Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with close to 20 years of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset โ€” but with compassion, not complexity.

From hospital medicine to the gym floor, from patient care to personal growth โ€” every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper.

๐Ÿ’ก Topics include:

Obesity & metabolic health

Longevity & fitness

Nutrition & preventive medicine

Doctor insights from close to 20 years in hospitals across the US!

Mindset, mental health, and motivation

๐ŸŽง Subscribe for weekly conversations that are honest, empowering, and rooted in science โ€” all from a doctor who believes medicine should heal the mind and body.